Search | Feedback | Contents | Deutsch
 
 
Organ of the
 

 GD — Society for Dermopharmacy

   
 
Home
Issue 2/2006
Issue 1/2006
Issue 2/2005
Issue 1/2005
Issue 1/2004
Issue 2/2003
Issue 1/2003
Issue 2/2002
Issue 1/2002
Issue 4/2001
Issue 3/2001
Issue 2/2001
Issue 1/2001
Issue 1/2000
Newsletter
 
 
More Links:
 
 
Society for
Dermopharmacy
 
 
 
 
 
  Issue 1 (2005)

GD News
Commitment for quality assurance

GD issues two further new guidelines focusing on dermopharmaceutical topics


The GD has published two additional novel guidelines in expression of its obligation for quality assurance in the field of Dermopharmacy. On initiative of the GD Task Force "Licht.Hautkrebs.Prävention" (Light.Skin Cancer.Prevention), the guideline "Actinic Keratosis" has been elaborated. This guideline has been established in cooperation with the Deutsche Dermatologische Gesellschaft (DDG) (German Dermatological Society) and other organizations and published as stage 2-guideline in the guideline register of the Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) (Working Group of Scientific Medicinal Departments) in January 2005. The second new guideline is entitled "Dermocosmetics for the Cleansing and Care of the Skin Prone to Acne", and represents a result elaborated by the GD department Dermocosmetics.
By means of the two new guidelines, the number of guidelines established by the GD itself or in cooperation with other organizations has meanwhile increased to six. Further guidelines published to date deal with dermatological prescriptions, occupational skin care agents, dermocosmetics for the cleansing and care of dry skin as well as dermocosmetic sun protection.

A must - treatment
of actinic keratoses



The new guideline "Actinic Keratosis" is divided into the chapters definition, etiology, and epidemiology, clinic and histology, clinical diagnostics, therapy and prevention. It is explicated regarding epidemiology that actinic keratosis occur very frequently with light-skinned persons and show an increased prevalence in particular in regions with high UV irradiation. For Europe a study from Great Britain has been cited according to which a prevalence of 15 percent for men and six percent for women in the adult population has to be reckoned with. A much higher prevalence is however reported from Australia where actinic keratosis has been determined in the age group of 30 to 70 years 55 percent of men and 37 percent of women are concerned by actinic keratoses.

As the actinic keratosis represents a carcinoma in situ and at approximately ten percent of patients it may pass over to an invasive epithelioma, it should be subject to treatment, in the opinion of the author committee of the guideline. The guideline lists all relevant studies and assesses them according to evidence levels pursuant to the criteria proposed by Sackett among the available operative, physical and pharmacological therapy procedures. Mentioned is also the significance of light protecting agents as one of several measures of prevention not only of the actinic keratosis, but also of the entirety of skin tumours.

Impure skin requires
special cosmetics



The guideline "Dermocosmetics for the Cleansing and Care of the Skin Prone to Acne" established by the department Dermocosmetics also aims at prevention. This guideline not only addresses physicians but also all persons developing, producing, testing, analyzing, selling or giving advice for the application of dermocosmetics devised for the cleansing and care of skin tending to acne. It recommends tests to be performed as to effectiveness and tolerability for products for skin cleansing or skin care for which the purpose "to be used at skin prone to acne" or "use at impure skin" is indicated. The related products are to contribute to the regeneration of a normal skin condition by reducing the present surplus of the sebaceous gland lipids on the skin surface, diminishing the population with acne-relevant bacteria and positively influence a possible existing inflammatory variance. They are not to interfere with parallel used acne therapeutics but should ideally counteract possible therapy-related side effects.

The performed effectiveness and tolerability proofs should be documented and made accessible to the consultative expert groups.

The two now guidelines have been archived, as all other GD guidelines, under the internet address www.gd-online.de. The guideline "Dermocosmetics for the Cleansing and Care or Skin Prone to Acne" has furthermore been published in this online-issue.


top

July 2005 Copyright © 2000 - 2014 Institute for Dermopharmacy GmbH. Contact: webmaster@gd-online.de